{"entity":{"id":"nct05471843","kind":"trial","name":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","aka":[],"tldr":"A phase 1/2 trial of Sonrotoclax in mantle cell lymphoma, run by BeiGene, active and no longer recruiting.","summary":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma is a phase 1/2 interventional study registered as NCT05471843 by BeiGene, with 125 participants enrolled, started 2022-09-05 and due to reach its primary completion in 2025-07-18. Interventions recorded: BGB-11417. Conditions listed: Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05471843","url":"https://clinicaltrials.gov/study/NCT05471843"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":["bcl2-inhibitors","kinase-inhibitors"],"targets":[],"drugs":["sonrotoclax"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05471843","phase":"1/2","setting":"A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma","sponsor":"BeiGene","started":"2022-09-05","startedType":"actual","yearReported":2026,"enrolled":125,"enrolledBasis":"registry","outcomes":[{"endpoint":"Part 2: Overall Response Rate (ORR) as Assessed by the Independent Review Committee (IRC)","primary":true,"unit":"%","arms":[{"name":"Part 2: Sonrotoclax 320 mg (Daily Ramp-up)","n":43,"value":44.2,"note":"95% CI 29.1 to 60.1; Figures from the ClinicalTrials.gov results section (first posted 2026-09-22), not from a publication"},{"name":"Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up)","n":60,"value":58.3,"note":"95% CI 44.9 to 70.9"},{"name":"Part 2: Sonrotoclax 320 mg Total","n":103,"value":52.4,"note":"95% CI 42.4 to 62.4"}],"source":"https://clinicaltrials.gov/study/NCT05471843?tab=results"},{"endpoint":"Part 1: Overall Survival (OS)","unit":"months","arms":[{"name":"Part 1: Sonrotoclax 160 mg (Daily Ramp-up)","n":10,"value":11.4,"note":"95% CI 0.7 to NA; Figures from the ClinicalTrials.gov results section (first posted 2026-09-22), not from a publication"},{"name":"Part 1: Sonrotoclax 320 mg (Daily Ramp-up)","n":12,"value":9.5,"note":"95% CI 0.7 to NA"}],"source":"https://clinicaltrials.gov/study/NCT05471843?tab=results"}]},"route":"/trials/nct05471843/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}